Fifteen residues comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-25. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Neighbouring countries were aware of the high levels of pollution in the Soviet Union but after the dissolution of the Soviet Union it was discovered that its environmental problems were greater than what the Soviet authorities admitted. The Soviet Union was the world's second-largest producer of harmful emissions. In 1988, total emissions in the Soviet Union were about 79% of those in the United States. But since the Soviet GNP was only 54% of that of the United States, this means that the Soviet Union generated 1.5 times more pollution than the United States per unit of GNP. The Chernobyl disaster in the Ukrainian SSR in 1986 was the first major accident at a civilian nuclear power plant. Unparalleled in the world, it resulted in a large number of radioactive isotopes being released into the atmosphere. Radioactive doses were scattered relatively far. Although long-term effects of the accident were unknown, 4,000 new cases of thyroid cancer which resulted from the accident's contamination were reported at the time of the accident, but this led to a relatively low number of deaths (WHO data, 2005). The disaster contributed to the socio-economic crises that resulted in the collapse of the Soviet Union. Another major radioactive accident that took place in the USSR was the Kyshtym disaster. The Kola Peninsula was one of the places with major problems. Around the industrial cities of Monchegorsk and Norilsk, where nickel, for example, is mined, all forests have been destroyed by contamination, while the northern and other parts of Russia have been affected by emissions.
Eukaryotic cells were created some 2.2 billion years ago in a process called eukaryogenesis. This is widely agreed to have involved symbiogenesis, in which an archaean and a bacterium came together to create the first eukaryotic common ancestor. It evolved into a population of single-celled organisms that included the last eukaryotic common ancestor, gaining capabilities along the way. This cell had a new level of complexity, with a nucleus and facultatively aerobic mitochondria. It featured at least one centriole and cilium, sex (meiosis and syngamy), peroxisomes, and a dormant cyst with a cell wall of chitin and/or cellulose. The last eukaryotic common ancestor gave rise to the eukaryotes' crown group, containing the ancestors of animals, fungi, plants, and a diverse range of single-celled organisms. The green plants were created around 1.6 billion years ago with a second episode of symbiogenesis that added chloroplasts, derived from cyanobacteria.
== Evolution == 3-Phosphoglycerate dehydrogenase possesses less than 20% homology to other NAD-dependent oxidoreductases and exhibits significant variance between species. There does appear to be conservation in specific binding domain residues, but there is still some variation in the positively charged active site residues between variants. For example, Type III PHGDH enzymes can be broken down into two subclasses where the key histidine residue is replaced with a lysine residue.
Sources: en.wikipedia.org
Over the following days, Stephen Miller asked "by what right does Denmark assert control over Greenland?", said Denmark and nations in general unable to defend their territory forgo their claim, and that it was both the formal position of the US government and obvious for security that Greenland should be part of the US. Asked repeatedly whether he would rule out taking Greenland by force, he refused but said that such questions are moot: "Nobody's going to fight the United States militarily over the future of Greenland." Trump emphasized the acquisition of Greenland by the US "from the standpoint of national security". The leaders of NATO members France, Germany, Italy, Poland, Spain, and the United Kingdom expressed their support for Denmark in a joint statement, stating that "Greenland belongs to its people, and only Denmark and Greenland can decide on matters concerning their relations", stressed they were keen on Arctic security but this had to be achieved by NATO allies collectively, and called for upholding the principles of the UN Charter, including sovereignty, territorial integrity, and the inviolability of borders.
=== Storyteller === Conway styles himself "Furrydom's Storyteller", making annual appearances at Anthrocon in what has come to be known as Uncle Kage's Story Hour. The entertainment typically consists of four or five extended personal anecdotes. His stage name resulted from his first storytelling experience at ConFurence in 1994, and derives from his fandom name Kagemushi Goro (Shadow Bug Goro), a reference to Kagemusha. Conway is regularly invited to tell his stories at other fan conventions, including I-CON, Eurofurence, ConClave, and Camp Feral!. Gross sales from recordings of his Story Hours were over US$2600 in 2004; no profit was realized, as the intention was to increase membership and awareness of Anthrocon.
Expectations diminished as a result of numerous failed replications, the retraction of several previously reported positive replications, and the identification of methodological flaws and experimental errors in the original study. By late 1989, most scientists considered cold fusion claims dead, and cold fusion subsequently gained a reputation as pathological science. In 1989 the United States Department of Energy (DOE) concluded that the reported results of excess heat did not present convincing evidence of a useful source of energy and decided against allocating funding specifically for cold fusion. A second DOE review in 2004, which looked at new research, reached similar conclusions and did not result in DOE funding of cold fusion. Presently, since articles about cold fusion are rarely published in peer-reviewed mainstream scientific journals, they do not attract the level of scrutiny expected for mainstream scientific publications. Some interest in cold fusion has continued through the decades—for example, a Google-funded failed replication attempt was published in a 2019 issue of Nature. A small community of researchers continues to investigate it, often under the alternative designations low-energy nuclear reactions (LENR) or condensed matter nuclear science (CMNS).
Sources: en.wikipedia.org
=== Overexpression === Mayford and colleagues engineered transgenic mice that express CaMKII with a point mutation of Thr-286 to aspartate, which mimics autophosphorylation and increases kinase activity. These mice failed to show LTP response to weak stimuli, and failed to perform hippocampus-dependent spatial learning that depended on visual or olfactory cues. Researchers speculate these results could be due to lack of stable hippocampal place cells in these animals. However, because genetic modifications might cause unintentional developmental changes, viral vector delivery allows the mice's genetic material to be modified at specific stages of development. It is possible with viral vector delivery to inject a specific gene of choice into a particular region of the brain in an already developed animal. This, in fact, has been done by Tonegawa group in early 1990s and by Poulsen and colleagues in 2007. Both groups used this method to inject CaMKII into the hippocampus. They found that overexpression of CaMKII resulted in slight enhancement of acquisition of new memories.
=== Potential technology === A new family of LEDs are based on the semiconductors called perovskites. In 2018, less than four years after their discovery, the ability of perovskite LEDs (PLEDs) to produce light from electrons already rivaled those of the best performing OLEDs. They have a potential for cost-effectiveness as they can be processed from solution, a low-cost and low-tech method, which might allow perovskite-based devices that have large areas to be made with extremely low cost. Their efficiency is superior by eliminating non-radiative losses, in other words, elimination of recombination pathways that do not produce photons; or by solving outcoupling problem (prevalent for thin-film LEDs) or balancing charge carrier injection to increase the EQE (external quantum efficiency). The most up-to-date PLED devices have broken the performance barrier by shooting the EQE above 20%. In 2018, Cao et al. and Lin et al. independently published two papers on developing perovskite LEDs with EQE greater than 20%, which made these two papers a mile-stone in PLED development. Their device have similar planar structure, i.e. the active layer (perovskite) is sandwiched between two electrodes. To achieve a high EQE, they not only reduced non-radiative recombination, but also utilized their own, subtly different methods to improve the EQE. In the work of Cao et al., researchers targeted the outcoupling problem, which is that the optical physics of thin-film LEDs causes the majority of light generated by the semiconductor to be trapped in the device.
Major Charles Karu Singleton, The Princess of Wales's Royal Regiment, 565366. Staff Sergeant Charlotte Louise Spence, Royal Army Physical Training Corps, W1060016. Major Jonathan Grant Studwell, Intelligence Corps, 30170101. Major Thomas Daniel Sweeney, Army Air Corps, 24757307. Sergeant Edward William Swindell, , Corps of Royal Engineers, Army Reserve, 30150063. Major Francesca Louise Sykes, Royal Regiment of Artillery, 30067880. Lieutenant Colonel Andrew James Teeton, Corps of Royal Engineers, 536346. Major (now Acting Lieutenant Colonel) James Viney, Corps of Royal Engineers, 25185183. Captain (now Acting Major) David Edward Williams, Corps of Royal Electrical and Mechanical Engineers, 24929032. Master Aircrew Oliver Martin Dewey, Royal Air Force, 30060196. Sergeant (now Acting Flight Sergeant) George Joseph Downey, Royal Air Force, L8516771. Wing Commander Sam Haley, Royal Air Force, 30000089. Squadron Leader James Duncan Hemingfield, Royal Air Force, 8700294K. Sergeant Martin John Henderson, Royal Air Force, 30112261. Squadron Leader Sharon Ingle, Royal Air Force, 30091084. Flight Sergeant (now Acting Warrant Officer) Stewart Marcus Jackson, Royal Air Force, F8427999. Flight Sergeant Philip Kipling, Royal Air Force, D8411323. Squadron Leader Kevin Charles William March, Royal Air Force, 30035301. Squadron Leader Christopher Scott Middleton, Royal Air Force, 2642751S. Squadron Leader Mark Shipley, Royal Air Force, 30001963. Warrant Officer Garry John Stanton, Royal Air Force, K8421673.
Prior to its inclusion in newborn screening, short-chain acyl-CoA dehydrogenase deficiency (SCADD) was thought to be life-threatening. Most patients identified via newborn screening as having this enzyme deficiency were asymptomatic, to the extent that SCADD was removed from screening panels in a number of regions. Without the cohort of patients identified by newborn screening, this clinical phenotype would likely not have been identified.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.